Teaneck-based Cognizant, a services provider to the life sciences industry, announced Tuesday it has agreed to acquire Zenith Technologies, a life sciences manufacturing technology firm based in Cork, Ireland.
Zenith Technologies is a manufacturer of software systems, Cognizant said. It has operating hubs in Ireland, Germany, India, Singapore, the United States.
The acquisition will enhance Cognizant’s capabilities in end-to-end operational and information technology systems for “smart factories” or biopharmaceutical and medical device manufacturers, it said. It will also deliver a range of Industry 4.0 capabilities, including factory design consultation, machine sensor and controller instrumentation, supervisory control, data acquisition, and more.
“Industry 4.0 solutions, encompassing Internet of Things (IoT), automation and analytics, are a strategic focus area for Cognizant,” Cognizant CEO Brian Humphries said. “In acquiring Zenith Technologies, we expand Cognizant’s IoT portfolio and extend our life sciences domain expertise by becoming a single-source provider of end-to-end smart factory capabilities. Together, we are better positioned to help clients realize information and operational technology convergence in their manufacturing operations, and advance the development of life-saving drugs, biologics, specialized pharmaceuticals and medical devices. We look forward to welcoming Zenith Technologies’ employees to Cognizant.”
Under terms of the acquistion, Zenith Technologies’ 800 workers will become part of Cognizant’s Life Sciences business unit.
The deal is expected to close in the third quarter of 2019. Financial terms were not disclosed.
“In joining Cognizant, we are bringing together two respected life sciences service provider brands with complementary technology and manufacturing operations expertise,” Zenith Technologies CEO Joe Haugh said. “It’s an exciting time for us, with the life sciences industry embracing digital transformation to enable more flexible and efficient manufacturing facilities to bring new treatments to market faster. Our combined business will drive process excellence through tighter integration of manufacturing processes and systems, the efficient harnessing of information and analytics across the manufacturing value chain, and the adoption of IoT technologies delivering manufacturing 4.0. Together, we are well-positioned to help clients more efficiently produce the life-changing medicines and medical devices for patients who need them most.”
